English
Современные возможности улучшения качества жизни пациентов с внутренними стентами
DOI: https://dx.doi.org/10.18565/urology.2018.2.134-140
А.Г. Мартов, Д.В. Ергаков, А.Б. Новиков
ФГБУ ГНЦ ФМБЦ им. А. И. Бурназяна ФМБА России, кафедра урологии и андрологии (заведующий кафедрой – д.м.н., проф. А. Г. Мартов), Москва, Россия; ГБУЗ «Городская клиническая больница № 57» Департамента здравоохранения г. Москвы (главный врач – к.м.н. И. А. Назарова), Москва, Россия; Многопрофильный медицинский центр Банка России (главный врач – д.м.н. А. М. Черкашов), Москва, Россия
Литература
1. Zenkov S.S. Internal drainage of the upper urinary tract. Ph.D. Thesis 1998. Russian (Зенков С.С. Внутреннее дренирование верхних мочевыводящих путей. Дисс. к.м.н., 1998 г.). 2. Martov A.G., Ergakov D.V., Kornienko S.I., Aboyan I.A., Pavlov S.V., Asfandiyarov F.R., Kalashnikov E. Improving the quality of life of patients with internal stents by changing their shape. Urologiia. 2011;2:7–13. Russian (Мартов А.Г., Ергаков Д.В., Корниенко С.И., Абоян И.А., Павлов С.В., Асфандияров Ф.Р., Калашников Е.С. Улучшение качества жизни больных с внутренними стентами путем изменения их формы. Урология. 2011;2:7–13). 3. Martov A.G., Maksimov V.A., Ergakov D.V., Miroshnikov V.M., Asfandiyarov F.R., Kalashnikov E.S. The use of tamsulosin in the prevention and treatment of stent-related symptoms. Urologiia. 2010;1:3–8. Russian (Мартов А.Г., Максимов В.А., Ергаков Д.В., Мирошников В.М., Асфандияров Ф.Р., Калашников Е.С. Применение тамсулозина в профилактике и лечении стентзависимых симптомов. Урология. 2010;1:3–8). 4. Hao P., Li W., Song C., Yan J., Song B., Li L. Clinical Evaluation Of Double-Pigtail in Patients with Upper Urinary Tract Diseases: Report of 2685 cases. J Endourol. 2008;22:65–70. 5. Ho C.H., Chen S.C., Chung S.D., Lee Y.J., Chen J., Yu H.J., Huang K.H. Determining the Apropriate Length of a Double-Pigtail Ureteral Stent by Both Stent Configurations and Related Symptoms. J Endourol. 2008;22:1427–1431. 6. Joshi H.B., Newns N., Stainthorpe A., MacDonagh R.P., Keeley F.X. Jr, Timoney A.G. Ureteral stent symptom questionnaire: Development and validation of a multidimensional quality of life measure. J Urol. 2003;169:1060–1064. 7. Borboroglu P.G., Amling C.L., Schenkman N.S., Monga M., Ward J.F., Piper N.Y., Bishoff J.T., Kane C.J. Ureteral stenting after ureteroscopy for distal ureteral calculi: a multi-institutional prospective randomized controlled study assessing pain, outcomes and complications. J Urol. 2001;166:1651–1657. 8. Lee C., Kuskowski M., Premoli J., Skemp N., Monga M. Randomized evaluation of Ureteral Stents using validated Symptom Questionnaire. J Endourol. 2005;19:990–993. 9. Hruby G.W., Ames C.D., Yan Y., Monga M., Landman J. Correlation of ureteric length with anthropometric variance of surface body habitus. BJU Int. 2007;99:1119–1122. 10. Mendez-Probst C.E., Goneau L.W., MacDonald K.W., Nott L., Seney S., Elwood C.N., Lange D., Chew B.H., Denstedt J.D., Cadieux P.A. The use of triclosan eluting stents effectively reduces ureteral stent symptoms: A prospective randomized trial. BJU Int. 2012;110:749–754. 11. Vanderbrink B.A., Rastinehead A.R., Ost M.C., Smith A. Encrusted Urinary Stents: Evaluation and Endourologic Management. J Endourol. 2008;22:905–912. 12. Riedl C.R., Witkowski M., Plas E., Pflueger H. Heparin coating reduces encrustation of ureteral stents: A preliminary report. Int J Antimicrob Agents. 2002;19:507–510. 13. Liatsikos E.N., Hom D., Dinlenc C.Z., Kapoor R., Alexianu M., Yohannes P., Smith A.D. Tail Stent versus reentry tube: A randomized comparison after percutaneous stone extraction. Urology 2002;59:15–19. 14. Beiko D.T., Knudsen B.E., Denstedt J.D. Advances in Ureteral Stent Design. J Endourol. 2003;17:195–199. 15. Dunn M.D., Portis A.J., Kahn S.A., Yan Y., Shalhav A.L., Elbahnasy A.M., Bercowsky E., Hoenig D.M., Wolf J.S. Jr, McDougall E.M., Clayman R.V. Clinical effectiveness of new stent design: Randomized single-blind comparison of tail and double pig-tail stents. J Endourol. 2000;14:195–202. 16. Damiano R., Autorino R., De Sio M., Cantiello F., Quarto G., Perdonà S., Sacco R., D’Armiento M. Does the size of ureteral stent impact urinary symptoms and quality of life? A prospective randomized study. Eur Urol. 2005;48:673–678. 17. Beiko D.T., Watterson J.D., Knudsen B.E., Nott L., Pautler S.E., Brock G.B., Razvi H., Denstedt J.D. Double-blind Randomized Control Trial Assessing the Safety and Efficacy of Intravesical Agents for Ureteral Stent Symptoms after Extracorporeal Shockwave Lithotripsy. J Endourol. 2004;18:723–730. 18. Gupta M., Patel T., Xavier K., Maruffo F., Lehman D., Walsh R., Landman J. Prospective randomized evaluation of periureteral botulinum toxin type A injection for ureteral stent pain reduction. J Urol. 2010;183:598–602. 19. Deliveliotis C., Chrisofos M., Gougousis E., Papatsoris A., Dellis A., Varkarakis I.M. Is there a role for alpha1-blockers in treating double-J stent-related symptoms? Urology. 2006;67:35–39. 20. Dellis A.E., Keeley F.X. Jr, Manolas V., Skolarikos A.A. Role of a-blockers in the treatment of stent-related symptoms: A prospective randomized control study. Urology. 2014;83:56–61. 21. Wang C.J., Huang S.W., Chang C.H. Effects of specific alpha1A/1D blocker on lower urinary tract symptoms due to double-J stent: A prospectively randomized study. Urol Res. 2009;37:147–152. 22. Lee Y.J., Huang K.H., Yang H.J., Chang H.C., Chen J., Yang T.K. Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy. Urolithiasis. 2013;41:247–252. 23. El-Nahas A.R., Tharwat M., Elsaadany M., Mosbah A., Gaballah M.A. A randomized controlled trial comparing alpha blocker (tamsulosin) and anticholinergic (solifenacin) in treatment of ureteral stent-related symptoms. World J Urol. 2016;34:963–968. 24. Lim K.T., Kim Y.T., Lee T.Y., Park S.Y. Effects of tamsulosin, solifenacin, and combination therapy for the treatment of ureteral stent-related discomforts. Korean J Urol. 2011;52: 485–488. 25. Park J., Yoo C., Han D.H., Shin D.W. A critical assessment of the effects of tamsulosin and solifenacin as monotherapies and as a combination therapy for the treatment of ureteral stentrelated symptoms: A 2•2 factorial randomized trial. World J Urol. 2015;33:1833–1840. 26. Park S.C., Jung S.W., Lee J.W., Rim J.S. The Effects of Tolterodine ER and Alfuzosin for the Treatment of Double-J Stent-Related Symptoms. J. Endourol. 2009;23:1913–1917. 27. Tehranchi A., Rezaei Y., Khalkhali H., Rezaei M. Effects of Terazosin and Tolterodine on ureteral stent related symptoms: A double-blind placebo-controlled randomized clinical trial. Int Braz J Urol. 2013;39:832–840. 28. Sivalingam S., Streeper N.M., Sehgal P.D., Sninsky B.C., Best S.L., Nakada S.Y. Does combination therapy with tamsulosin and tolterodine improve ureteral stent discomfort compared with tamsulosin alone? A double-blind, randomized, controlled trial. J Urol. 2016;195:385–390. 29. Zhou L., Cai X., Li H., Wang K.J. Effects of a-blockers, antimuscarinics, or combination therapy in relieving ureteral stent-related symptoms: A meta-analysis. J Endourol. 2015;29:650–656. 30. Katz I.R., Sands L.P., Bilker W., DiFilippo S., Boyce A., D’Angelo K. Identification of medications that cause cognitive impairment in older people: The case of oxybutynin chloride. J Am Geriatr Soc. 1998;46:8–13. 31. Martov A.G., Maksimov V.A., Ergakov D.V., Davydova S.S., Asfandiyarov F.R., Kalashnikov E.S. The use of tolterodine in the treatment of symptoms associated with the presence of internal stent in patients. Ural’skii meditsinskii zhurnal. 2012;2(94):18–26. Russian (Мартов А.Г., Максимов В.А., Ергаков Д.В., Давыдова С.С., Асфандияров Ф.Р., Калашников Е.С. Применение толтеродина в лечении смптомов, связанных с наличием у пациентов внутреннего стента. Уральский медицинский журнал. 2012;2(94):18–26).
Об авторах / Для корреспонденции
А в т о р д л я с в я з и: А. Г. Мартов – д.м.н., профессор, заведующий кафедрой урологии и андрологии ГБУ ГНЦ ФМБЦ
им. А. И. Бурназяна ФМБА России, Москва, Россия; e-mail: martovalex@mail.ru
Похожие статьи
